Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio ViewXTAE:BIOV +0.12%41 EV-to-FCF is -2.22 as of Aug. 31, 2026. GuruFocus rates XTAE:BIOV with a GF Score™ of 41/100 and a GF Value™ of ₪1.71 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 412 Medical Devices & Instruments companies, Bio View ranks worse than 242718.2% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Bio View's Enterprise Value is ₪6.92 Mil.
Bio View's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was ₪-3.11 Mil. Therefore, Bio View's EV-to-FCF for today is -2.22.
The historical rank and industry rank for Bio View's EV-to-FCF or its related term are showing as below:
XTAE:BIOV'
s EV-to-FCF Range Over the Past 10 Years
Min: -300.95 Med: 7.44 Max: 86.6
Current: -2.22
During the past 13 years, the highest EV-to-FCF of Bio View was 86.60. The lowest was -300.95. And the median was 7.44.
XTAE:BIOV's EV-to-FCF is ranked worse than 100% of 412
companies
in the Medical Devices & Instruments industry
Industry Median: 24.61
vs XTAE:BIOV: -2.22
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Bio View's share price for today is ₪0.816.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bio View's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was ₪-1.130.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Bio View EV-to-FCF Related Terms
Bio View EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Bio View's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Bio View's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio View EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio View's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Bio View's EV-to-FCF falls into.
Bio View's current Enterprise Value is ₪6.92 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Bio View's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was ₪-3.11 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio View (XTAE:BIOV) has a EV-to-FCF of -2.22 as of Aug. 31, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bio View and its competitors. According to the industry distribution chart, Bio View ranks #999999 out of 412 companies in the Medical Devices & Instruments industry.
Is Bio View's EV-to-FCF too high?
Bio View's current EV-to-FCF is -2.22. Based on the distribution chart, Bio View ranks #999999 out of 412 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bio View has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bio View's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bio View ranks #999999 out of 412 companies for EV-to-FCF. This places Bio View in the lower half of its industry. The industry median EV-to-FCF is 24.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 24.61, based on 412 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Bio View and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 24.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio View's current EV-to-FCF is -2.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio View stock overvalued right now?
Based on GuruFocus' analysis, Bio View (XTAE:BIOV) is currently considered Possible Value Trap. The stock's GF Value™ is ₪1.71, compared to a current price of ₪0.82 — trading 52.3% below its estimated fair value. The current EV-to-FCF is -2.22. Bio View's overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Bio View (XTAE:BIOV), the current EV-to-FCF is -2.22 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio View (XTAE:BIOV) Overvalued in 2026?
Based on GuruFocus' analysis, Bio View stock appears to be undervalued.
The current stock price of ₪0.82 is trading 52.3% below its estimated GF Value™ of ₪1.71.
GuruFocus considers Bio View to be Possible Value Trap.
Key valuation signals for XTAE:BIOV:
EV-to-FCF: -2.22
GF Value™: ₪1.71 vs. price of ₪0.82 (52.3% below fair value)
No single metric tells the full story. See the XTAE:BIOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio View Ltd is an Israel based company engaged in the research, development, manufacture, marketing, and sale of computerized systems for identification of rate cells and test for detection of cancer. It manufactures and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, pathology clinical and research laboratories. Geographically, the group has its business presence in Israel, USA, and other countries, of which majority of the revenue is derived from the USA.
41GF Score
Get the complete analysis for XTAE:BIOV
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTAE:BIOV has been successfully added to your 
